Friday, 23 February, 2024

31 Mar 2012 | Australasian Dental Practice

news > Spectrum > Page 14

A billion carpules later and 3M ESPE Ubistesin is finally here!

By Joseph Allbeury

New Products

3M ESPE is launching its Ubistesin range of articaine hydrochloride local anaesthetics for dentistry in Australia after gaining regulatory approval last year. Available in New Zealand and internationally in 57 countries for over a decade, Ubistesin Articaine HCl 4% will be available in two formulations for routine and complicated procedures requiring prolonged anaesthesia exclusively through Gunz Dental from April.


"We're excited to be able to offer Australian clinicians the Ubistesin range of local anaesthetics that have proven to be so popular globally," said 3M ESPE Senior Product Manager Gabrielle O'Carroll. "Ubistesin is the number two brand worldwide and we've produced over a billion carpules in the last 10 years and 120 million last year alone."

"We are delighted to be partnering with 3M ESPE to launch Ubistesin, a product that has more than 30 years of clinical evidence to support it," said Gunz Dental's Managing Director, Trevor Martin. "In our opinion, Ubestesin will help dental professionals to improve their consistency and quality of patient care."

The Ubistesin range is manufactured at the former ESPE facility in Seefeld, Germany outside Munich with the production of local anaesthetic being a staple of the company before its acquisition by 3M in 2001 that resulted in the formation of 3M ESPE.

With over 50 years of manufacturing experience in dental local anaesthetics, the company has a proven process to ensure that the high quality local anaesthetic is checked and safeguarded.

Even the packaging has been continuously refined and includes the following well-thought-of features:

  • Cylindrical glass ampoules with inner silicone coating - for a smooth, gentle and controlled injection;
  • Safety foil - prevents splintering;
  • Packaging in a stable metal tin with a padded interior - for safe transport, easy removal and tidy storage; and
  • Colour-coded aluminium caps - No chance of mix-ups!

The rapid metabolism and high plasma protein binding of Articaine allows for a 4% articaine formulation that results in profound anaesthesia.

Due to this higher efficacy, it is possible to decrease the volume and lower the epinephrine concentration to 1:200.000 for routine dental procedures.

The high plasma binding rates of Articaine lead to low systemic toxicity and shortest elimination half-time. As a result, Ubistesin is a least risk anaesthetic for the majority of patients.

"A number of clinical studies in recent years have demonstrated Articaine's superiority for infiltration anaesthesia, particulary in the mandible", said Stephen Langdon, Scientific Affairs Manager for 3M ESPE. "Articaine is not only less cardio-depressant but also less vasodilative than lidocaine and therefore can and should be combined with lower epinephrine concentrations in routine dental procedures".

Beginning April 1, 2012, 3M ESPE will market two formulations of Articaine in the Australian market; Ubistesin Articaine HCl 4% with Adrenaline 1:200 000 and Ubistesin Forte Articaine HCl 4% with Adrenaline 1:100 000.

"When you combine the profound benefits of rapid metabolism, high plasma protein binding, high lipid solubility and enhanced tissue penetration, clinical needs and patient benefits are well met with the use of Articaine" said Mr Langdon.

Dental practitioners are reminded to review the Product Information sheet before administering these products. The Product information Sheet is available from 3M ESPE, Gunz Dental and by visiting www.ebs.tga.gov.au.

Related Products

Related Contacts

From the editor

Clinical

Clinical

Clinical

Stream the latest dental videos...
SofaCON 2020: What does the future of Infection Control look like post-COVID-19?

Sponsored Links...

Upcoming Events...

Feb 23 2024
Feb 29 2024
Mar 06 2024
Mar 09 2024
Mar 12 2024
Mar 13 2024
Mar 13 2024
Mar 14 2024

Expodental 2024

Madrid, SPAIN

Mar 15 2024
Mar 16 2024
Mar 21 2024

ADX24 Sydney

Sydney, AUSTRALIA

Mar 22 2024
Apr 05 2024
Apr 12 2024
Apr 16 2024

Dentists Behaving 'Very' Badly

Brisbane, AUSTRALIA

Apr 19 2024
Apr 19 2024

IDEM Singapore 2024

Singapore, SINGAPORE

Apr 23 2024
Apr 24 2024
May 01 2024
May 02 2024
May 09 2024
May 11 2024
May 14 2024
May 22 2024
May 24 2024
May 29 2024
May 30 2024
May 31 2024

Scottish Dental Show 2024

Glasgow, UNITED KINGDOM

May 31 2024

Famdent Show Mumbai 2024

Mumbai, INDIA

Jun 01 2024
Jun 06 2024
Jun 09 2024
Jun 11 2024
Jun 22 2024
Jul 16 2024
Jul 25 2024
Aug 23 2024
Aug 29 2024

Practical Endodontics Workshop

Sydney, AUSTRALIA

Sep 07 2024
Sep 14 2024
Sep 26 2024
Oct 03 2024
Oct 10 2024
Oct 17 2024

ADOHTA 2024 National Congress

Sydney, AUSTRALIA

Oct 24 2024
Nov 13 2024
Nov 29 2024
Mar 25 2025

IDS 2025

Cologne, GERMANY

May 08 2025